Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
NCT ID: NCT06389552
Last Updated: 2024-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
36 participants
OBSERVATIONAL
2023-09-25
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma
NCT02959879
Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
NCT03590275
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
NCT05529940
FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer
NCT02351219
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT05360732
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
* ECOG 0 or 1
* Scheduled to RO or R1 resection
* Organ function capable of chemotherapy
Exclusion Criteria
* Palliative Therapy
* Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HK inno.N Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Myung-Ah Lee
Role: STUDY_CHAIR
Seoul St. Mary's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul ST. Mary's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Myung-Ah Lee
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IN_CTP_N01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.